Explore: Cetuximab
Discover books, insights, and more — all in one place.
Learn more about Cetuximab with top reads curated from trusted sources — all in one place.
AI-Generated Overview About “cetuximab”:
Books Results
Source: The Open Library
The Open Library Search Results
Search results from The Open Library
1An inquiry into the ImClone cancer-drug story
By United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.
“An inquiry into the ImClone cancer-drug story” Metadata:
- Title: ➤ An inquiry into the ImClone cancer-drug story
- Author: ➤ United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.
- Language: English
- Number of Pages: Median: 759
- Publisher: ➤ For sale by the Supt. of Docs., U.S. G.P.O. [Congressional Sales Office] - U.S. G.P.O.
- Publish Date: 2002
- Publish Location: Washington
“An inquiry into the ImClone cancer-drug story” Subjects and Themes:
- Subjects: ➤ Cetuximab - Corrupt practices - Drugs - ImClone Systems Incorporated - Insider trading in securities - Testing - Drugs, testing - Business enterprises, corrupt practices
- Places: United States
Edition Identifiers:
- The Open Library ID: OL14530356M
- Online Computer Library Center (OCLC) ID: 51586262
- Library of Congress Control Number (LCCN): 2003426647
- All ISBNs: 0160694396 - 9780160694394
Author's Alternative Names:
"United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations"Access and General Info:
- First Year Published: 2002
- Is Full Text Available: No
- Is The Book Public: No
- Access Status: No_ebook
Online Marketplaces
Find An inquiry into the ImClone cancer-drug story at online marketplaces:
- Amazon: Audiable, Kindle and printed editions.
- Ebay: New & used books.
Wiki
Source: Wikipedia
Wikipedia Results
Search Results from Wikipedia
Cetuximab
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic
Alpha-gal syndrome
drug cetuximab, and discovered that these individuals had IgE antibodies in their blood that were specifically targeted to the portion of cetuximab which
Adagrasib
the United States in December 2022 for lung cancer and together with Cetuximab in 2024 for colorectal cancer. Adagrasib is indicated for the treatment
Monoclonal antibody
MAbs approved by the FDA for cancer include: Alemtuzumab Bevacizumab Cetuximab Dostarlimab Gemtuzumab ozogamicin Ipilimumab Nivolumab Ofatumumab Panitumumab
Ménétrier's disease
infiltrative disorders such as sarcoidosis. Cetuximab is the first-line therapy for Ménétrier disease. Cetuximab is a monoclonal antibody against epidermal
Encorafenib
V600K mutation, as detected by an FDA-approved test; in combination with cetuximab, for the treatment of adults with metastatic colorectal cancer with a
Panitumumab
the labels of two anti-EGFR monoclonal antibody drugs (panitumumab and cetuximab) indicated for the treatment of metastatic colorectal cancer to include
Samuel D. Waksal
At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration
Merck Group
marketed product is Erbitux (cetuximab), for which it has marketing rights worldwide, apart from North America. (Cetuximab was discovered by Imclone Systems
Amblyomma americanum
non-primate mammals, alpha-gal is also found in cat dander and in the drug cetuximab. Allergic reactions to alpha-gal usually occur 3–6 hours after consuming